Meta-analysis · people

Cerebrolysin beat placebo on global change in Alzheimer's at 6 months

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

In pooled placebo-controlled trials, Cerebrolysin improved overall clinical ratings in mild-to-moderate Alzheimer's with safety similar to placebo, though its effect on cognition alone was clear only at 4 weeks.

Kind
Meta-analysis
Studied in
People
Published
2015
Journal
Dement Geriatr Cogn Disord

What they tested

The team set out to measure the benefits and risks of Cerebrolysin in people with mild-to-moderate Alzheimer's disease by pooling all randomized, double-blind, placebo-controlled trials, while avoiding flaws of an earlier meta-analysis.

How the study was done

A meta-analysis, which pools results from several studies, of 6 randomized, double-blind trials that compared Cerebrolysin at 30 ml/day with placebo (a dummy treatment) in people with mild-to-moderate Alzheimer's disease. The pooled data covered results at 4 weeks and 6 months, and drew on individual patient data, published group results or both.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Cerebrolysin did better than placebo on cognitive function at 4 weeks (standardized mean difference -0.40; 95% CI -0.66 to -0.13), but the gap at 6 months (-0.37; 95% CI -0.90 to 0.16) was not statistically significant. On global clinical change, an overall rating of how a patient was doing, the odds of improving favored Cerebrolysin at both 4 weeks (odds ratio 3.32) and 6 months (odds ratio 4.98). A combined measure of global change plus cognition also favored Cerebrolysin at both time points (Mann-Whitney 0.57 each time). Side effects and other safety measures were similar to placebo.

What it doesn’t show

The pooled results cover two time points, 4 weeks and 6 months, and mix individual patient data with published group results across 6 trials. The cognitive benefit seen at 4 weeks was not statistically significant at 6 months.

The paper

Gauthier et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015.

The compound

More studies on Cerebrolysin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo